Health: National strategy to accelerate the field

Digital health

The emergence of new technologies is disrupting the health sector where digital is at the heart of the revolution. It is the bearer of a strong ambition to invent an effective response to the challenges of the sector and accelerate the shift towards so-called “5P” medicine: personalized, preventive, predictive, participative and evidence-based. This digital transformation in health must be carried out for the benefit of the general population and patients.

Emerging infectious diseases – CBRN threats

The Covid-19 pandemic illustrates the major impacts that the emergence of new pathogens can have even beyond the health issue. The MIE-MN (Emerging Infectious Diseases and Nuclear, Radiological, Biological and Chemical Threats) acceleration strategy aims to enable the State to understand, prevent and control the emergence or re-emergence of infectious diseases.

Biotherapy and bioproduction innovative therapies

The strategy promotes the emergence of new technologies as well as the scaling up of existing technologies in order to reduce the cost of access to these new therapeutic products. In the long term, it is a question of increasing French sovereignty in terms of health.

Example of current calls for projects :

i-Demo : project support R&D structuring

Goal

This system supports the development of very innovative products or services with high added value. It also supports demonstrators on an industrial or pre-industrial scale of innovations at an advanced development stage (prototype in a representative environment, pilot lines).

Beneficiaries

Companies alone or in collaboration with up to 6 partners, including at least one SME or ETI.

Projects

This call for projects is generic for projects that do not fall within the themes covered by the acceleration strategies.
Projects, lasting between 36 and 60 months, must present a total expenditure base of more than €2 million for individual projects and more than €4 million for collaborative projects.

Public co-financing

Mix of grants and repayable advances, depending on the nature of the project and the size of the company

Closing Date

Several intermediate dates for submitting projects until May 3, 2022

Innovations in biotherapies

Goal

The AAP aims to support the development of innovative solutions in terms of either biotherapies in human health, or the development of R&D or stratification tools for the development of biotherapies.

Beneficiaries

Mono-partner project or carried by a consortium made up of at least one SME or ETI.

Projects

The projects must have a structuring effect on the sector, and include dimensions of innovation, relocation or reinforcement.
A first preclinical proof of concept is awaited.

Public co-financing

The aid is subject to the RDI regime: between 25% and 80% of the amount of eligible expenses depending on the nature of the project and the size of the company.
60% to 75% of subsidies, the rest in reimbursable advance.

Closing Date intermediaries

November 21, 2023
Intermediate statements on May 17, 2022, November 23, 2022, May 23, 2023

Health 2030 Industrialization and Capacities

Goal

Finance industrialization projects on:
– Biotherapies and bioproduction of innovative therapies;
– emerging infectious diseases and CBRN threats;
– medical devices and in vitro diagnostic devices.

Beneficiaries

Companies alone or in collaboration. Companies carrying less than 5% of the total amount are supported by other partners or subcontractors.

Projects

Projects involving industrial investment expenditure, and which may include an innovation dimension:
- Production unit
– Pilot line,
– Process qualification equipment,
– Multimodal platforms…

Public co-financing

Mix of grants and repayable advances, depending on the nature of the project and the size of the company.

Closing Date

Several intermediate dates for submitting projects until January 9, 2024

Scroll to Top